Esther Krofah is the executive director of FasterCures, a center of the Milken Institute. She has deep experience in the government, nonprofit, and for-profit sectors, where she has led efforts to bring together diverse stakeholder groups to solve critical issues and achieve shared goals that improve the lives of patients. Most recently, Krofah was the director of public policy leading GlaxoSmithKline's engagement with the U.S. Department of Health and Human Services (HHS) and relevant Executive Branch agencies on broad health-care policy issues, including leadership in improving vaccinations and care for people living with HIV. Prior to GSK, Krofah served as the deputy director of HHS' Office of Health Reform, where she led the development of policy positions for significant regulatory priorities, including the health insurance marketplaces. Prior to HHS, Krofah served as a program director at the National Governors Association (NGA) health-care division, working directly with governors' health policy advisors, state Medicaid directors, and state health commissioners on health insurance, health workforce, and Medicaid coverage issues. Before joining the NGA, Krofah worked in consulting at Deloitte Consulting LLP, where she worked with public sector and commercial clients, including assisting states in developing state-based exchanges. Krofah received a B.A. from Duke University and a Masters of Public Policy from the Harvard University John F. Kennedy School of Government.
Conversations with Mike Milken
Keeping track of rapid-pace global developments in treatments and vaccines for COVID-19 may seem to be an uphill battle. But since February, Esther Krofah’s team at FasterCures has been producing exactly that: a real-time tool that, as of late May 2020, is monitoring development of more than 200 treatments and 140 vaccines.